title: [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
abstract: Teriparatide is the recombinant N-terminal fragment (1-34) of endogenous human parathyroid hormone (PTH) and has been approved and used in many countries including the United States and Europe. Treatment with teriparatide 20 microg/day for 18 months increased spine bone mineral density (BMD) by approximately 10% and reduced the incidence of vertebral fractures by 65% and nonvertebral fragility fractures by 53%. Furthermore, the results from paired-biopsy showed that the treatment with teriparatide improved bone architecture. Teriparatide is being developed in Japan as a treatment for osteoporosis.
authors.affiliation: Eli Lilly Japan K.K., Lilly Research Laboratories Japan, Japan Clinical Research.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Naohiko
authors.initials: N
authors.lastname: Wakayama
authors.forename: Akimitsu
authors.initials: A
authors.lastname: Miyauchi
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D019379:Teriparatide / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide